IGH/MAF Plus Translocation, Dual Fusion
- MAF, 16q23.1-q23.2, Red
- IGH, 14q32.33, Green
The IGH/MAF Plus product consists of probes, labelled in green, proximal to the Constant, and within the Variable segment of the IGH region and MAF probes, labelled in red. The MAF probe mix contains two probes centromeric to the MAF gene (145kb and 91kb) covering part of the WWOX gene and includes the D16S3213 and the D16S3029 markers. The other two probes, telomeric to MAF cover 119kb and 125kb regions and include the RH69965 and the D16S3073 markers respectively.
The translocation t(14;16)(q32.3;q23) involving MAF and IGH is present in 25% of myeloma cell lines1, in 5% of primary Multiple Myeloma samples2,3and results in high levels of MAF expression.
Patients harbouring the t(14;16) appear to have a worse outcome3,4. The majority of the breakpoints are dispersed over a region of approximately 500kb, centromeric to the MAF proto-oncogene at 16q23. Another breakpoint has been observed that is telomeric to MAF1. Translocations with the centromeric breakpoints place MAF under the control of strong 3' IGH enhancers. Recent gene expression profiling of myeloma cell lines revealed that MAF caused transactivation of cyclin D2 (a promoter of cell cycle progression), thus enhancing proliferation of myeloma cells4.
Within or near to the MAF/IGH breakpoint region lies the putative tumour suppressor gene, WWOX, which spans the common chromosomal fragile site 16D (FRA16D) at chromosome 16q23.3-24.1 – a region that is a frequent target for both loss of heterozygosity and chromosomal rearrangements in ovarian, breast, hepatocellular and prostate carcinomas as well as other neoplasias5.
In our hands, Cytocell FISH probes, including the ROS1 Proximal and ROS1 Distal probes, have proven to be of the highest quality with bright, easy to interpret signals, thus providing confidence in our results. Cytocell’s customer support is outstanding, as their staff are extremely knowledgeable and truly care about their customers and their customers’ needs. Jennie Thurston, Director of Cytogenetics at Carolinas Pathology Group
1. Chesi M et al., Blood 1998;91(12):4457-63
2. Avet-Loiseau H et al., Blood 2002;99(6):2185-91
3. Fonseca R et al., Blood 2003;101(11):4569-75
4. Chang H et al., Leukemia 2007;21:1572-4
5. Nunez MI et al., BMC Cancer 2005;5:64
- Area of Interest*
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.